Gene Symbol: GRIA4
Gene Name: Glutamate Ionotropic Receptor AMPA Type Subunit 4
Chromosomal Location: 11q22.1
Aliases: GluR4, GluR-D, GLUR4, GLURD
GRIA4 encodes the GluR4 subunit of the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor, one of the three main types of ionotropic glutamate receptors in the central nervous system. AMPA receptors mediate the majority of fast excitatory synaptic transmission and are critical for synaptic plasticity, learning, and memory.
¶ Protein Structure and Function
The GRIA4 protein forms part of the AMPA receptor complex, which typically consists of four subunits (GRIA1-4). Key features include:
- Ligand-binding domain: Binds glutamate, the primary excitatory neurotransmitter
- Ion channel: Permeates Na+ and Ca2+ ions upon activation
- Transmembrane domains: Four transmembrane segments that form the channel pore
- C-terminal tail: Involved in intracellular signaling and receptor trafficking
AMPA receptors can be homomeric (containing one subunit type) or heteromeric (containing multiple subunit types). GRIA4-containing receptors often co-assemble with other subunits, particularly GRIA2.
GRIA4 and other AMPA receptor subunits are affected in Alzheimer's disease:
- Synaptic dysfunction: Altered AMPA receptor trafficking and composition in AD hippocampus
- Excitotoxicity: Dysregulated Ca2+ influx through AMPA receptors may contribute to excitotoxic cell death
- Memory impairment: AMPA receptor dysfunction is linked to synaptic plasticity deficits in AD
In Parkinson's disease, GRIA4 plays a role in:
- Striatal synaptic plasticity: Altered AMPA receptor function in the basal ganglia
- L-DOPA-induced dyskinesia: Changes in AMPA receptor subunit composition associated with dyskinesias
- Dopaminergic neuron survival: Glutamate excitotoxicity may contribute to neurodegeneration
GRIA4 expression is altered in ALS:
- Motor neuron vulnerability to excitotoxicity
- Changes in glutamate transporter expression
- Potential therapeutic target
GRIA4 mutations have been linked to:
- Early-onset epileptic encephalopathies
- Intellectual disability
- Autism spectrum disorders
| Brain Region |
Expression Level |
Notes |
| Hippocampus |
High |
CA1, CA3, dentate gyrus |
| Cerebral Cortex |
High |
Layer 2/3 pyramidal neurons |
| Cerebellum |
Moderate |
Purkinje cells |
| Basal Ganglia |
Moderate |
Striatum |
| Brainstem |
Low |
Motor nuclei |
- AMPA receptor modulators: Positive allosteric modulators being investigated for cognitive enhancement
- Antagonists: Potential for neuroprotection but limited by side effects
- Trafficking modulators: Targeting receptor internalization
- Cognitive enhancement: AMPAkines (AMPA receptor potentiators)
- Neuroprotection: Modulating excitotoxicity
- Parkinson's treatment: Addressing L-DOPA-induced dyskinesias
¶ Interactions and Pathways
GRIA4 interacts with:
- GRIA1, GRIA2, GRIA3: Other AMPA subunits
- GRIP1, GRIP2: PDZ domain proteins
- PICK1: Protein interacting with C kinase
- NSF: N-ethylmaleimide-sensitive factor
- Glutamate signaling: Ionotropic glutamate receptor pathway
- Synaptic plasticity: Long-term potentiation/depression
- Calcium signaling: Ca2+-dependent signaling cascades
GRIA4 polymorphisms have been associated with:
- schizophrenia
- Bipolar disorder
- Alzheimer's disease risk
- Epilepsy susceptibility
Pathogenic GRIA4 mutations cause:
- Early-onset epileptic encephalopathy (DEE)
- Developmental delay
- Intellectual disability
- How do GRIA4-containing AMPA receptors differ in neurodegeneration?
- Can AMPA receptor modulation slow disease progression?
- What determines subunit-specific vulnerability?
- AMPA receptor potentiators for AD cognitive impairment
- Gene therapy approaches
- Understanding subunit-specific trafficking